References
- 1. Štvrtinová V, Labaš P. Venózny trombomembolizmus - definícia, princípy a metódy prevencie. In: Štvrtinová V, editor. Venózny tromboembolizmus: prevencia, diagnostika, liečba. 2.revised ed. Bratislava: Herba; 2009. p. 15-26.
- 2. Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011; 13: 1-16. DOI: 10.1097/GIM.0b013e3181faa0f2
- 3. Arsov T, Miladinova D, Spiroski M. Factor V Leiden Is Associated with Higher Risk of Deep Venous Thrombosis of Large Blood Vessels. Croat Med J 2006; 47 (3): 433-439.
- 4. Deitcher SR, Rodgers GM. Thrombosis and Antithrombotic Therapy. In: Pine JW, Jr., editor. Wintrobe’s clinical hematology. 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 1464-1508.
- 5. Zaher GF, Abdelaal MA. Venous Thromboembolism in Cancer Patients. In: Abdelaal MA, editor. Pathophysiology and Clinical Aspects of Venous Thromboembolism in Neonates, Renal Disease and Cancer Patients. 1st ed. Rijeka: InTech; 2012. p. 73-114.
- 6. Kwaan HC. Double Hazard of Thrombophilia and Bleeding in Leukemia. ASH Education Book 2007; 2007 (1): 151-157. DOI: 10.1182/asheducation-2007.1.151
- 7. Hofírek I. Angiologie. In: Souček M, editor. Vnitřní lékařství: 1. díl. 1. ed. Praha - Brno: Praha Grada Publishing - Brno Facta Medica - Brno Muni Press; 2011. p. 174-182.
- 8. Hasegawa S, Aoyama T, Kakinoki R, Toguchida J, Nakamura T. Bilateral phlegmasia dolens associated with Trousseau’s syndrome: a case report. Arch Phys Med Rehabil 2008; 89 (6): 1187-90. DOI: 10.1016/j.apmr.2007.10.030.
- 9. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: An oral direct inhibitor of factor Xa. Am J Health-Syst Pharm 2008; 65: 1520-9. DOI: 10.2146/ajhp070624
- 10. Xarelto. [cit. 2014-07-01]. Access at webpage: <http://www.adcc.sk/web/humanne-lieky/spc/xarelto-spc-50321.html>
- 11. Cushman M. Epidemiology and Risk Factors for Venous Thrombosis. Semin Hematol 2007; 44 (2): 62-69.
- 12. Kubisz P, Staško J. Tromboembolická choroba, trombofilné stavy. In:Kubisz P, Staško J, editors. Hematológia a transfuziológia. 1. ed. Bratislava - Praha: Grada Slovakia - Grada, Publishing; 2006. p. 193-216.
- 13. Schulman S, Marder VJ, White II, GC. Overview of Venous Thromboembolism. In: Marder VJ. editor. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia: Wolters Kluwer, Lippincott Williams & Wilkins; 2013. p. 957-961.
- 14. Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2 (8038): 581-4.
- 15. Oehadian A, Iqbal M, Sumantri R. Deep Vein Thrombosis in acute myelogenous leukemia. Acta Med Indones- Indo J Intern Med 2009; 41 (4): 200-4.
- 16. Parekh PJ, Merrell J, Clary M, Brush JE, Johnson DA. New Anticoagulants and Antiplatelet Agents Am J Gastroenterol 2014; 109 (1): 9-19. DOI: 10.1038/ajg.2013.228.
- 17. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M, Pauker SG, Makdissi R, Guyatt GH. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e351S-e418S. DOI: 10.1378/chest.11-2299
- 18. Karetová D. Choroby žil. In: Klener P, editor. Vnitřní lékařství. 4th revised and supplemented ed. Prague: Galen, Karolinum; 2011. p. 351-361.